NIH Initiates its P-I Trial for COVID-19 at KPWHRI in Seattle

 NIH Initiates its P-I Trial for COVID-19 at KPWHRI in Seattle

MVC Collaborates with the US NIH to Develop Vaccine Against Corona Virus

Shots:

  • The study involves assessing of investigational vaccine mRNA-1273 against COVID-19 enrolling 45 patients with age of 18 to 55 years ~6wks. and the first patient has been dosed. Additionally, National Institute of Allergy and Infectious Diseases (NIAID) is funding the P-I trial
  • The study will be evaluating two doses of the vaccine (IM, 25mcg, 100/250 mcg) in the upper arm ~ for 28 days apart due to its safety, and the ability to induce immune response. Till Mar 15, 2020 WHO has reported 153,517 cases of COVID-19 and 5,735 deaths worldwide with confirmed 2,800 cases and 58 deaths in the US
  • mRNA-1273 is an investigational vaccine developed by NIAID scientists in collaboration with Moderna. Additionally, the adults in Seattle who are interested in joining the study needs to visit https://corona.kpwashingtonresearch.org

Click here to read full press release/ article | Ref: NIH | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post